Additional file 2: Table S1. of Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Authors :: Arnold, Douglas
Calabresi, Peter
Kieseier, Bernd
Shifang Liu
Xiaojun You
Fiore, Damian
Hung, Serena
Publication Year :: 2017
Publisher :: Figshare, 2017.
Abstract: Summary of MRI endpoints over 2 years by original randomisation group [6]. (DOC 53kb)

Full Text Access

Tools